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Abstract
Background
Infections and primary graft dysfunction are devastating complications in the immediate
postoperative period following lung transplantation. Nowadays, reliable diagnostic tools are
not available. Biomarkers could improve early infection diagnosis.
Methods
Multicentre prospective observational study that included all centres authorized to perform
lung transplantation in Spain. Lung infection and/or primary graft dysfunction presentation
during study period (first postoperative week) was determined. Biomarkers were measured
on ICU admission and daily till ICU discharge or for the following 6 consecutive postopera-
tive days.
Results
We included 233 patients. Median PCT levels were significantly lower in patients with no
infection than in patients with Infection on all follow up days. PCT levels were similar for
PGD grades 1 and 2 and increased significantly in grade 3. CRP levels were similar in all
groups, and no significant differences were observed at any study time point. In the absence
of PGD grade 3, PCT levels above median (0.50 ng/ml on admission or 1.17 ng/ml on day 1)
were significantly associated with more than two- and three-fold increase in the risk of infec-
tion (adjusted Odds Ratio 2.37, 95% confidence interval 1.06 to 5.30 and 3.44, 95% confi-
dence interval 1.52 to 7.78, respectively).
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Conclusions
In the absence of severe primary graft dysfunction, procalcitonin can be useful in detecting
infections during the first postoperative week. PGD grade 3 significantly increases PCT lev-
els and interferes with the capacity of PCT as a marker of infection. PCT was superior to
CRP in the diagnosis of infection during the study period.
Introduction
Infection and primary graft dysfunction (PGD) are the most common and devastating compli-
cations in the immediate postoperative period following lung transplantation (LT) [1].
According to the registry of the International Society for Heart and Lung Transplantation, in a
total of 45,542 lung transplants the major reported causes of death within the first 30 days after
transplantation were PGD (24.3%) and non-CMV infections (19.3%) [2]. Direct contact of the
allograft with the environment, impaired clearance mechanisms caused by allograft denerva-
tion and profound immunosuppression, especially in the first postoperative days, explain this
high vulnerability of LT recipients to infection.
Early diagnosis of infectious complications after LT is imperative. This allows prompt initi-
ation of antimicrobial therapy and adjustment of immunosuppressant therapy, and can pre-
vent infection-related morbidity and mortality [3,4]. However, some characteristics inherent
to lung transplantation make this early diagnosis difficult. The need for higher immunosup-
pression as compared with other allografts can mask common infectious symptoms like fever
and delay infection recognition. In addition, lung infection and PGD share respiratory failure
and lung infiltrates on chest X-ray as the most common symptoms making differential diagno-
sis complicated [5]. As diagnostic errors in these vulnerable patients can have harmful conse-
quences, reliable diagnostic tools are desirable.
Various studies have demonstrated that procalcitonin (PCT) is a useful diagnostic marker
of infection in different critical patient groups [6]. In transplant recipients, PCT has been
shown on several occasions to be a valuable parameter for detecting infection in liver and
heart transplant recipients [7–11]. However, few data have been published on PCT after lung
transplantation, and none on PGD. Only 2 studies, 1 of them published by our group, have
evaluated the benefit of PCT as a diagnostic marker of infection. Although the findings were
promising, the quality of the studies was marred by the small sample size. Therefore, the role
of C reactive protein (CRP) in this context remains unclear.
The aims of the study were to determine how serial determination of PCT and CRP can
improve the diagnosis of early infectious complications after lung transplantation, and to
determine whether their predictive accuracy is affected by the presence of PGD.
Methods
Study design and setting
Full names of all hospitals and approving IRBs/ethics committees are: University Hospital
Reina Sofia (Cordoba): Comite´ de E´tica de la Investigacio´n de Co´rdoba. University Hospital
Vall’dHebron (Barcelona): Comite´ E´tico de Investigacio´n Clı´nica del Hospital Universitario
Vall d’Hebron. University Hospital Puerta de Hierro (Madrid): Comite de evaluacio´n de inves-
tigacio´n con medicamentos CEIm. University Hospital La Fe (Valencia): Comite´ Etico de
Investigacio´n Biomedica. University Hospital A Coruña (La Coruña): Fundacio´n Profesor
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Novoa Santos. University Hospital 12 de Octubre (Madrid): Comite´ de Etica Hospital 12 de
Octubre. University Hospital Marques de Valdecilla (Santander): Comite´ Etico de Investiga-
cion Clinica de Cantabria.
We conducted a multicentre prospective observational study between September 2014 and
September 2015. The study included all 7 centres authorized to perform lung transplantation
in Spain. All data regarding lung transplantation are available on the Spanish National Trans-
plant Organization website [12].
The study period included the first 7 postoperative days after lung transplantation. Clinical
and demographic characteristics of all patients, including age, gender, type of transplant (sin-
gle or bilateral), need for extracorporeal membrane oxygenation (prior to transplantation, dur-
ing or/and after surgery), cold ischemia time, infection diagnosis, source of infection, length of
ICU and hospital stay and ICU and hospital mortality were recorded. Patients were divided
into 2 groups depending on the presence of infectious complications during the study period
(day of ICU admission and the following 6 days after lung transplantation). Lung Infection
[13] and primary graft dysfunction [14] were defined according to the International Society
for Heart and Lung Transplantation definitions, and ordinal categorized according to severity.
Severe PGD was defined as PGD grade 3.
Methods of measurement
Biomarkers were measured on ICU admission (day 0) and daily till ICU discharge or for the
following 6 consecutive postoperative days, as appropriate. Except for day 0, blood samples
were obtained at 7 am. In all cases, biomarkers were assessed in real time.
Serum PCT was measured with a time-resolved amplified cryptate emission technology
assay (Kryptor PCT; Brahms, Hennigsdorf, Germany). This assay is based on a polyclonal anti-
body against calcitonin and on a monoclonal antibody against katacalcin. Antibodies bind to
the calcitonin and katacalcin sequence of precursor molecules. This assay has an optimised
functional sensitivity of 0.06 mcg/L.
CRP concentrations were measured by immunoturbidimetry using a modular analyser
(Roche Diagnostics, Meylan, France).
Statistical analysis
Categorical and discrete variables were expressed as counts (percentage) and continuous vari-
ables as mean ± standard deviation or median and 25–75 percentile (Interquartile Range) in
case of not normally distributed variables such as PCT and CRP levels. Statistical differences
between groups were assessed by the chi-square test, using Yates’ correction or Fisher’s exact
test for categorical variables when appropriate. U Mann Whitney and Kruskall Wallis tests
were used for PCT and CRP levels and other not normally distributed variables, and the stu-
dent’s t test was used for the remaining continuous variables.
To compare the accuracy of PCT levels to predict the risk of suffering ‘Infection’ for each
day of follow-up, receiver operating characteristic (ROC) curves were constructed and the
areas under the curve (AUC) with their 95% confidence intervals (95% CI) were determined.
To estimate the strength of association, the PCT values were divided into dichotomous vari-
ables using the median split method, and adjusted odds ratios (OR) with their 95% CI for the
risk of suffering ‘Infection’ were calculated using unconditional logistic regression. The follow-
ing potential confounders were pre-established for inclusion in the models: sex, age (as a
continuous variable), necessity of post-operative Extracorporeal Membrane Oxygenation
(ECMO) (yes/no), creatinine levels (as a continuous variable), type of lung transplant (single
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or double-lung transplantation) and transplant centre (hospital). Analysis was stratified
according to the presence or absence of PGD Grade 3.
The level of statistical significance was set at 0.05, and all tests were two-tailed. We used the
SPSS statistical software package 22.0 (SPSS, Inc., Chicago, Ill) for all statistical analyses.
All donation permissions were obtained according to Spanish donor laws. This includes the
need of specific permission signed by patient relatives. In particular, in this study we have not
used donated tissue/organs from any vulnerable populations. The hospital’s ethics committees
of all participant centres accepted the study and informed consent was obtained from partici-
pants for inclusion in this study and for the use of their clinical samples and data in research.
Results
Demographic and clinical characteristics
Two hundred and thirty three consecutive patients (148 men, mean age 52.97 ± 11.86 years)
underwent single (n = 108, 46.4%) or bilateral (n = 125, 53.6%) LT for pulmonary fibrosis
(44.6%), emphysema (20.6%), COPD (15%) and other causes (19.8%). Inclusion by hospital
was as follows: University Hospital “Marques de Valdecilla” (Santander) 41 patients (17.6%),
University Hospital “A Coruña” (La Coruña) 38 patients (16.3%), University Hospital “Vall
d’Hebron” (Barcelona) 38 patients (16.3%), University Hospital “Puerta de Hierro” (Madrid)
35 patients (15%), University Hospital “Doce de Octubre” (Madrid) 29 patients (12.4%), Uni-
versity Hospital “Reina Sofı´a” (Co´rdoba) 29 patients (12.4%) and University Hospital “La Fe´”
(Valencia) 23 patients (9.9%). Baseline characteristics are shown in Table 1.
With respect to overall complications, 52 patients developed infection and 28 PGD. S1
Table shows a cross-table of each complication. In total, 157 patients presented a normal post-
operative course without infection or PGD, 48 patients (20.6%) developed only ‘Infection’, 24
patients (10.3%) developed only ‘PGD grade 3’ and 4 patients (1.7%) developed ‘PGD grade 3’
followed by ‘Infection’ during follow-up.
Mean time between end of transplant surgery and diagnosis of infection was 2.23 ± 2.25
days (S2 Table). Infections were distributed as follows; ventilator-associated tracheobronchitis
(48%), ventilator-associated pneumonia (35%) and non-ventilator-associated pneumonia
(17%). The main organisms involved were Pseudomonas aeruginosa (43.2%), Methicillin-sus-
ceptible Staphylococcus aureus (15.5%), Serratia Marcescens (8.4%) and Methicillin-resistant
Staphylococcus aureus (7.6%). Patients who developed infectious complications more fre-
quently underwent bilateral LT, more frequently needed postoperative ECMO support and
developed significantly higher grades of PGD (Table 1).
No cases of early rejection or viral infection were observed during the study period. Eigh-
teen patients died after a median interval of 13 (range 2 to 112) days. The median length of
ICU stay was 7 (range 4 to 16) days for the overall population and 13 (range 6 to 29) days for
patients who developed infection.
Biomarker kinetic profiles and postoperative complications
Valid cases and descriptive statistics for PCT and CRP levels for each day of follow-up with
respect to Infection and PGD grade 3 are presented in S3 Table. PCT and CRP levels were not
normally distributed, distribution was very asymmetrical, and so medians and P5 and P75 per-
centile are presented as measures of central tendency and dispersion in Table 2. Both the PCT
and CRP biomarkers presented similar kinetics in all patients during the study period, with an
initial increase in levels, a plasma peak recorded in the first 48 hours, and a progressive decline
over the following days (Table 2).
Procalcitonin in lung transplantation
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Table 1. Baseline characteristics of the study population.
Overall population No infection Infection in trasplant recipient p value
N = 233 N = 181 N = 52
Age (years), median (IQR) 57 (48–61) 57 (48–61) 55.5 (48.5–61) 0.961
Male sex, n (%) 148 (63.5) 110 (60.8) 38 (73.1) 0.104
Disease that origins transplant, n (%) 0.845
Pulmonary fibrosis 104 (44.6) 81 (77.9) 23 (22.1)
Emphysema 48 (20.6) 35 (72.9) 13 (27.1)
COPD 35 (15.0) 28 (80.0) 7 (20.0)
Cystic fibrosis 18 (7.7) 14 (77.8) 4 (22.2)
Pulmonary hypertension 9 (3.9) 8 (88.9) 1 (11.1)
Others 15 (6.4) 11 (73.3) 4 (26.7)
Donor infection, n (%) 57 (24.5) 38 (21.0) 19 (36.5) 0.02
Single lung transplant, n (%) 108 (46.4) 93 (51.4) 15 (28.8) 0.004
Ischemia 1st lung (hours), median (IQR) 4.4 (4.0–5.2) 4.3 (3.4–5.0) 5.2 (4.4–5.9) 0.09
Ischemia 2nd lung (hours), median (IQR) 7.0 (6.0–7.4) 6.4 (5.3–7.1) 7.6 (6.7–9.1) 0.003
Intraoperative ECMO, n (%) 36 (15.5) 29 (16.0) 7 (13.5) 0.653
Postoperative ECMO, n (%) 13 (5.6) 7 (3.9) 6 (11.5) 0.034
Primary Graft Dysfunction (PGD) 0.018
No PGD 139 (59.7) 100 (55.2) 39 (75)
PGD Grade 1, n (%) 44 (18.9) 41 (22.7) 3 (5.8)
PGD Grade 2, n (%) 22 (9.4) 16 (8.8) 6 (11.5)
PGD Grade 3, n (%) 28 (12.0) 24 (13.3) 4 (7.7)
ICU stay (days), median (IQR) 6.9 (4.0–16.4) 5.9 (4.0–13.9) 12.9 (6.2–29.7) 0.19
Hospital stay (days), median (IQR) 32.9 (23.9–52.4) 29.9 (23.4–43.9) 46.9 (29.9–73.6) 0.37
ICU mortality, n (%) 14 (6.0) 7 (3.9) 7 (13.5) 0.01
Hospital mortality, n (%) 18 (7.7) 11 (6.1) 7 (13.5) 0.13
IQR = Interquartile Range.
https://doi.org/10.1371/journal.pone.0180202.t001
Table 2. Median levels for PCT and CRP levels for each day of follow-up, in ‘Infection’ and ‘primary graft dysfunction (PGD) grade 3’ specifically.
Overall No Infection Infection in trasplant recipient No PGD Grade 3 PGD Grade 3
N = 233 N = 181 N = 52 N = 205 N = 28
PCT LEVELS Median Median Median P value Median Median P value
Admiss 0.50 0.36 2.00 0.000 0.47 4.57 0.000
Day 1 1.17 1.01 3.83 0.000 1.07 4.90 0.000
Day 2 1.14 0.94 2.73 0.000 1.01 2.61 0.006
Day 3 0.70 0.55 1.60 0.000 0.69 1.32 0.402
Day 4 0.56 0.50 0.78 0.002 0.54 1.11 0.105
Day 5 0.28 0.20 0.40 0.006 0.28 0.48 0.680
Day 6 0.20 0.20 0.30 0.027 0.20 0.39 0.447
CRP LEVELS Median Median Median P value Median Median P value
Admiss 4.29 4.29 4.34 0.635 4.00 5.64 0.351
Day 1 12.32 12.25 12.90 0.539 12.90 11.40 0.722
Day 2 10.10 9.80 10.90 0.209 10.00 12.50 0.346
Day 3 5.97 5.76 6.60 0.153 5.72 8.46 0.345
Day 4 4.10 3.80 4.90 0.090 3.99 5.70 0.107
Day 5 3.01 2.55 4.10 0.086 2.62 5.40 0.034
Day 6 2.30 2.42 2.16 0.451 2.10 5.54 0.068
https://doi.org/10.1371/journal.pone.0180202.t002
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Primary graft dysfunction. With respect to PGD grades, 45 patients (19.3%) presented
PGD 1, 25 (10.7%) grade 2 and 28 (12%) PGD grade 3. PCT plasma levels were similar for
PGD grades 1 and 2 and increased significantly in the group of patients with PGD grade 3.
CRP levels were similar in all groups, and no significant differences were observed at any study
time point (Fig 1).
PCT levels were significantly higher in the first 3 postoperative days (day 0 to day 2) in the
‘PGD grade 3’ group vs. the rest of the study population, with a peak PCT plasma level observed
on day 1 (mean: 4.90 ng/ml). In the case of CRP, significant differences were observed only on
postoperative day 5 (p = 0.034) (Table 2).
Infection. Median PCT levels were significantly lower in patients with no infection than
in patients with ‘Infection’ on all follow up days. The greatest difference occurred between the
day of admission and day 3 (p<0.001). PCT plasma levels peaked on day 1 (median: 3.83 ng/
ml). In the case of CRP, the kinetic profile was similar in both groups, and no significant differ-
ences were observed with respect to the presence of infectious complications during the study
period (Table 2 and Fig 2).
Diagnostic accuracy and strength of association for PCT with respect to
infection
Table 3 shows the diagnostic accuracy of PCT values for detecting ‘infection’ for each day of
follow-up. According to the AUC levels, the diagnostic accuracy of PCT to determine the pres-
ence of infection was low (around 0.70) and increased slightly when focused exclusively on
Fig 1. Biomarker levels and primary graft dysfunction.
https://doi.org/10.1371/journal.pone.0180202.g001
Fig 2. Biomarker levels and postoperative infection.
https://doi.org/10.1371/journal.pone.0180202.g002
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patients without primary graft dysfunction. For CRP, AUC levels were lower than those
observed in PCT.
PCT levels were dichotomously categorized using the median split method in order to eval-
uate their strength of association with respect to infection (Table 4). During the first 5 postop-
erative days (day 0 to day 4), PCT levels above median value were statistically associated with a
higher risk of infection. Thus, PCT levels above 0.50 ng/ml on ICU admission (day 0) or 1.17
ng/ml on postoperative day 1 were associated with a two- and three-fold increase in the risk of
infection: OR 2.65; 95%CI (1.34–5.25) and OR 3.21; 95%CI (1.62–6.39), respectively. These
associations remain significant after adjusting for sex, age (as continuous variable), need for
postoperative Extracorporeal Membrane Oxygenation use (yes/no), creatinine levels (as a con-
tinuous variable), type of lung transplant (single or double-lung transplantation) and trasplant
centre (hospital). However, after stratifying by primary graft dysfunction, these associations
disappeared with respect to the group of patients with PGD 3 and increased in the No PGD 3
group. In the absence of PGD 3, therefore, previously described cut-off levels for day 0 and day
1 were significantly associated with a three- and four-fold increase in the risk of infection: OR
3.06; 95%CI (1.49–6.25), OR 4.10; 95%CI (1.99–8.46), respectively.
Discussion
Serum PCT levels are shown to be a good tool in diagnosing infectious complications after
lung transplantation. However, their accuracy in detecting infections depends on the coexis-
tence of severe PGD. CRP, meanwhile, was less useful than PCT in detecting postoperative
complications after LT, irrespective of their cause.
In transplant recipients, PCT has been shown to be elevated during bacterial infection and
to remain normal in the setting of acute rejection. However, most studies include mixed popu-
lations of solid organ transplant recipients, and only 2 have exclusively evaluated lung trans-
plant recipients. In agreement with our results, both studies lung transplant recipients
reported significantly higher peak PCT concentrations in patients with postoperative infection
[15,16]. However, our earlier study did not evaluate PGD, while Desmard et al. did not evalu-
ate the potential effect of PGD on the capacity of PCT to diagnose infection. The present
study, which has the largest sample size to date, highlights the confounding effect of PGD
grade 3 on the interpretation of PCT values. Therefore, although PCT did not detect subse-
quent development of infection in the subgroup of patients with PGD grade 3, it was shown to
be a useful marker of infection in the absence of PGD. Thus, PCT levels higher than 0.50 ng/
Table 3. Predictive accuracy of PCT values for each day of follow-up for the risk of infection, stratified by existence of primary graft dysfunction
(PGD) grade 3.
PCT LEVELS All Patients (N = 233) Without PGD Grade 3 (N = 205) With PGD Grade 3 (N = 28)
AUC 95% CI AUC 95% CI AUC 95% CI
Admiss 0.70 0.62 0.78 0.73 0.64 0.82 0.69 0.32 1.00
Day 1 0.70 0.61 0.79 0.73 0.64 0.82 0.57 0.24 0.90
Day 2 0.70 0.61 0.80 0.73 0.63 0.83 0.50 0.14 0.86
Day 3 0.71 0.61 0.80 0.73 0.64 0.83 0.38 0.08 0.67
Day 4 0.67 0.57 0.77 0.70 0.60 0.80 - - - - - -
Day 5 0.65 0.56 0.75 0.67 0.57 0.77 - - - - - -
Day 6 0.63 0.52 0.74 0.66 0.54 0.77 - - - - - -
AUC = Area Under the Curve; 95%CI = 95% Confidence Intervals
https://doi.org/10.1371/journal.pone.0180202.t003
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Table 4. Crude and adjusted odds ratios (OR) for PCT levels (according to median) in relation to existence or not of infection.
All Patients (N = 233)
Infection
PCT LEVELS Cut-off pointa NO (N) YES (N) ORcb (95% CI) ORac (95% CI)
Admiss <= .50 97 15 1.00 - - 1.00 - -
.51+ 78 32 2.65 1.34 5.25 2.78 1.10 7.05
Day 1 < = 1.17 99 14 1.00 - - 1.00 - -
1.18+ 77 35 3.21 1.62 6.39 3.07 1.39 6.82
Day 2 < = 1.14 86 13 1.00 - - 1.00 - -
1.15+ 63 35 3.68 1.80 7.51 3.24 1.46 7.20
Day 3 < = 0.695 67 11 1.00 - - 1.00 - -
0.696+ 48 30 3.81 1.74 8.34 3.73 1.49 9.36
Day 4 < = 0.56 64 11 1.00 - - 1.00 - -
0.57+ 46 27 3.42 1.54 7.58 3.29 1.31 8.30
Day 5 < = 0.28 57 13 1.00 - - 1.00 - -
0.29+ 47 23 2.15 0.98 4.69 2.33 0.92 5.92
Day 6 < = 0.20 46 12 1.00 - - 1.00 - -
0.21+ 38 19 1.92 0.83 4.44 2.10 0.69 6.44
Without PGD Grade 3 (N = 205)
Infection
PCT LEVELS Cut-off point NO (N) YES (N) ORcb (95% CI) ORac (95% CI)
Admiss <= .50 90 14 1.00 - - 1.00 - -
.51+ 61 29 3.06 1.49 6.25 2.85 1.07 7.59
Day 1 < = 1.17 95 13 1.00 - - 1.00 - -
1.18+ 57 32 4.10 1.99 8.46 3.90 1.64 9.23
Day 2 < = 1.14 80 12 1.00 - - 1.00 - -
1.15+ 51 32 4.18 1.97 8.86 3.76 1.57 9.01
Day 3 < = 0.695 63 10 1.00 - - 1.00 - -
0.696+ 42 29 4.35 1.92 9.86 4.94 1.73 14.13
Day 4 < = 0.56 62 10 1.00 - - 1.00 - -
0.57+ 40 27 4.19 1.83 9.57 4.81 1.72 13.44
Day 5 < = 0.28 53 12 1.00 - - 1.00 - -
0.29+ 42 23 2.42 1.08 5.42 2.71 0.99 7.42
Day 6 < = 0.20 44 11 1.00 - - 1.00 - -
0.21+ 34 19 2.24 0.94 5.32 2.10 0.63 7.04
With PGD Grade 3 (N = 28)
Infection
PCT LEVELS Cut-off point NO (N) YES (N) ORcb (95% CI) ORac (95% CI)
Admiss <= .50 7 1 1.00 - - 1.00 - -
.51+ 17 3 1.24 0.11 14.01 1.44 0.10 20.39
Day 1 < = 1.17 4 1 1.00 - - 1.00 - -
1.18+ 20 3 0.60 0.05 7.35 1.10 0.07 16.55
Day 2 < = 1.14 6 1 1.00 - - 1.00 - -
1.15+ 12 3 1.50 0.13 17.67 1.83 0.09 37.04
Day 3 < = 0.695 4 1 1.00 - - 1.00 - -
0.696+ 6 1 0.67 0.03 14.03 - - - - - -
Day 4 < = 0.56 2 1 1.00 - - 1.00 - -
0.57+ 6 0 - - - - - - - - - - - -
(Continued )
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ml on ICU admission or 1.17 ng/ml on postoperative day 1 were associated with a three- and
four-fold increase in risk of infection, respectively. These results support the potential utility of
PCT in infection diagnosis in this setting. Although the pathogenesis of PGD is multifactorial
and is still not fully understood, it seems to revolve around an ischemia-reperfusion phenome-
non that causes a powerful inflammatory reaction. Certain cytokines, such as IL-6 and IL-8 are
thought to be involved in the presentation and intensity of this clinical picture [17–20]. Simi-
larly, PCT synthesis is closely linked to cytokine-mediated signalling [21,22], and its secretion
is proportional to the magnitude of the underlying inflammatory process. This pathogenic
nexus would justify the elevated levels of PCT observed in our study patients with PGD grade
3 and the insignificant elevation in patients with less severe dysfunction (probably due to
insufficiently intense signalling). The small size of his series could have been a factor in Des-
mard’s failure to observe a correlation between PGD severity and PCT levels on postoperative
day 1 [16].
The procalcitonin kinetic profile was similar for all patients, irrespective of the presence of
complications or of their type. We observed an initial increase in PCT levels that peaked in the
first 48 hours, followed by a progressive decline to< 0.5 ng/ml on postoperative day 7 in all
cases. This is a common kinetic profile not only after lung transplantation and thoracic sur-
gery, but also in other types of solid organ transplantation and in major surgery [23–28]. The
difference between groups of patients, therefore, lies not in changes in PCT levels over time,
but in the peak level observed. This is why PCT trends (delta value) are meaningless in this
patient population. Even though Desmard et al. defend the utility of serial PCT determinations
in these patients, they themselves acknowledge that the high inter-individual variability in
PCT levels observed in the first postoperative week of their study limited the utility of this
marker. Infection correlated with de novo elevation in PCT values after postoperative day 6,
once levels had normalised [16]. The fact that PGD was not investigated as a confounding fac-
tor, even though it was observed in 35% of patients, could explain these results. In our study,
PCT levels obtained in the first postoperative day in patients with no PGD grade 3 were signifi-
cantly associated with a four-fold increase in the risk of infection, and were as reliable as those
obtained on the following days. Bearing in mind that microbiological identification and data
testing usually take at least 48 to 72 hours from the time the sample is obtained, PCT use could
contribute useful information in these patients. Moreover, classic signs of infection, such as
fever, may be masked by the use of steroids and other immunosuppressants, thus hindering
diagnosis of infection. Most immunosuppressants, such as azathioprine, cyclosporine, tacroli-
mus, corticosteroids and anti-interleukin 2 monoclonal antibodies, do not to appear to inter-
fere with PCT secretion [29–31], suggesting that it can be used in association with these drugs.
Elevated PCT levels on the first postoperative day, therefore, should prompt clinicians to start
Table 4. (Continued)
Day 5 < = 0.28 4 1 1.00 - - 1.00 - -
0.29+ 5 0 - - - - - - - - - - - -
Day 6 < = 0.20 2 1 1.00 - - 1.00 - -
0.21+ 4 0 - - - - - - - - - - - -
PGD = Primary Graft Dysfunction. (a) Levels categorized according to median. Levels < = cut-off point were taken as the reference category. (b) ORc
denotes Crude OR. CI denotes confidence interval. (c) ORa refers to OR adjusted for sex, age (as continuous variable), necessity of post-operative Extra
Corporeal Membrane Oxygenation (ECMO) (yes/no), creatinine levels (as continuous variable), type of lung transplant (single or double-lung
transplantation) and trasplant centre (hospital).
https://doi.org/10.1371/journal.pone.0180202.t004
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thorough microbiological tests, and even to step up antibiotic therapy. A drug-escalation algo-
rithm and intensified diagnostics based on daily PCT measurements in critically ill patients
failed to improve survival [32]. For that reason, clinical trials focused specifically on this popu-
lation are needed to confirm this hypothesis.
Regarding diagnostic accuracy, one of the problems with the test is the fact that the optimal
cut-off point varies from day to day and so makes it difficult to use in practice, because of it we
explored the strength of associations according to median split methods. PCT has so far been
shown to be superior to CRP in the diagnosis of infection in the immediate postoperative
period in transplant recipients. In this respect, most studies have focussed on liver and heart
recipients [8,24]. Although data relating to postoperative follow-up in lung recipients is scant,
and what little evidence is available is based on studies that have included both lung and heart
transplant recipients, the results seems to point in the same direction [9,10,33]. Thus, Hammer
et al. in a mixed population of heart transplant and lung transplant recipients found PCT levels
to be predictors of infection, and moreover to be directly correlated with severity of infection
[9,10]. In our previous study, albeit with a small sample size, PCT was shown to be superior to
CRP and leukocyte determination in infection diagnosis during the first week after lung trans-
plantation [15]. Our findings confirm the superiority of PCT over CRP in this context. Unlike
PCT, CRP was not useful in diagnosing the presence of infection, irrespective of the presence
or primary graft dysfunction. Furthermore, the use of CRP in postoperative follow-up of lung
transplant patients seems to be unjustified.
The main strength of this study, aside from the sample size, is the heterogeneity of the
patient population and its multicentre design. Seven hospitals across Spain, using different
antibiotic prophylaxis and immunosuppressive regimens, and with different local microbial
flora, participated in the trial. These characteristics support the potential external validity of
our findings.
Our study has several limitations. First, we investigated only the first 7 postoperative days
after lung transplantation. Our results, therefore, may not be valid for LT recipients developing
infection beyond this time period. Secondly, donor PCT levels were unknown, and therefore
early PCT measurements after LT could be influenced by donor secretion. Although little is
known of the effect of donor secretion, Eyraud et al., studying a liver transplant population,
showed high PCT peak levels in recipients to be associated with infection and cardiac arrest in
donors. [34]. In our study, PCT peak levels were obtained 48 hours after LT; bearing in mind
that the half-life of PCT is 24 hours, donor secretion is unlikely to have affected our measure-
ments. Thirdly, we did not consider the immunosuppressive therapy used in our patients.
However, as mentioned above, steroids and commonly used immunosuppressant drugs do
not interfere with PCT metabolism. None of the study centres used OKT-3, the only immuno-
suppressant known to interfere with PCT production and secretion [35]. Finally, the biomark-
ers were measured in real time and the results were available to the clinicians treating the
patients. It introduces a possibility of bias as the clinicians might rely on the biomarker for the
diagnosis of infection and PGD. In all cases investigators were encouraged to adhere to Inter-
national Society for Heart and Lung Transplantation definitions but the real time design of
this study makes this bias possible.
Conclusions
In the absence of severe PGD, PCT peak levels are useful in detecting the development of infec-
tious complications during the first postoperative week. PGD grade 3 significantly increases
PCT levels and interferes with the capacity of PCT as a marker of infection. PCT was superior
to CRP in the diagnosis of infection during the study period.
Procalcitonin in lung transplantation
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